PFIZER INC

Pfizer sells its Minipress antihypertensive line to Novartis India for ₹1 250 crore, refocusing on high‑growth pharma and sharpening its portfolio strategy.

Pfizer’s GLP‑1 weight‑loss strategy, spotlighted by the president’s personal transformation video, positions the company to win in China’s booming obesity drug market.

Pfizer’s 4% stock rally sparks concerns as a $1.2 billion Depo‑Provera settlement and a lagging R&D pipeline threaten the company’s high valuation and investor confidence.

Pfizer’s 2026 earnings reveal a 5% boost in non‑COVID sales, $9.7 B in cost‑savings, and a sharp focus on precision oncology to drive future growth.

Discover how Pfizer’s diversified portfolio and advanced therapeutics position it amid shifting tech‑driven market momentum and rising global drug demand.

Pfizer’s Q2 2026 earnings beat expectations with $15.03 bn revenue, lifts 2026 guidance, and signals resilience amid patent cliff pressures.

Pfizer’s Phase‑III win for Litfulo and EU approval of its updated COVID‑19 vaccine signal a new growth wave in dermatology and immunization, boosting investor confidence and shareholder returns.

Pfizer partners with Eisai to launch dual‑action migraine drug Nurtec in Japan, boosting revenue and market reach in the growing CGRP therapy space.

Pfizer wins FDA priority review for Talzenna + Xtandi, a dual‑mechanism therapy that could redefine first‑line treatment for metastatic prostate cancer.

Pfizer’s pivot from COVID‑EUA sales to booming oncology drives future growth, with analysts pointing to a $30.17 target and a robust pipeline.